Slingshot members are tracking this event:

FDA to Vote on Approval of Absorb GT1 Bioresorbable Vascular Scaffold (BVS) March 15

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Abbott Vascular filed for approval to the US FDA in Q2 of 2015 for its Absorb GT1 Bioresorbable Vascular Scaffold (BVS).  The FDA will meet, review and vote on Absorb on March 15, 2016.  Absorb functions as a permanent metal stent to open blocked arteries but is made of naturally dissolvable material that leaves behind a restored vessel.  Absorb is currently available in many countries worldwide, but is an investigational drug in the US.  Abbott also filed for regulatory approval for Absorb in China in 2015.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Absorb, Fda Approval, Gt1 Bioresorbable Vascular Scaffold, Coronary Artery Lesions